BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Euronext Paris 12:30:01 2024-04-26 pm EDT | ||
| 22.99 EUR | +1.53% |
|
| Current month | +49.55% | ||
| 1 month | +66.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 22.96 | +1.37% | 23 |
| 24-04-25 | 22.65 | +20.05% | 114 |
| 24-04-24 | 18.86 | +3.19% | 104 |
| 24-04-23 | 18.28 | -1.29% | 116 |
| 24-04-22 | 18.52 | +11.20% | 112 |
Real-time Euronext Paris
Last update April 26, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| PW80S | |
| ISIN | DE000SD5KMJ8 |
| Date issued | 2021-04-19 |
| Strike | 8,161 p |
| Maturity | Unlimited |
| Parity | 2 : 1 |
| Emission price | 1.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.08 € |
|---|---|
| Lowest since issue | 2.05 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.4
USD
Spread / Average Target
+10.08%
- Stock Market
- Certificates
- PW80S Certificat
